This Action aims at using innovative translational research to identify colorectal cancer biomarkers for personalized medicine that will improve screening, early detection and disease follow-up, and attain better tumor profiling, state-of-the-art functional characterization of genetic variants and new therapy approaches
This meeting will focus on Disease risk profiling (WG1). It will not include a Management Committee meeting. It could take place ONLINE due to the current circumstances.
This congress is organized by some participants of our COST Action (María José Serrano, Juan José Díaz, Carmen Garrido, José Antonio Lorente) and we are disseminating it to other participants in case they may be interested.